Raphael Pharmaceutical loses chairman and CFO, names new CFO amid cash crisis
RAPH filed a Executive and Board Changes on light trading volume (0.1× avg).
Summary
Raphael Pharmaceutical disclosed the resignations of Chairman Ajay Kumar Dhadha (effective June 30) and CFO/General Counsel/Director Guy Ofir (effective July 16). Uri Tadelis was appointed CFO the same day. The leadership shakeup occurs with the company holding only $1,000 in cash and facing a going concern warning.
Key Events · Executive and Board Changes · RAPH
-
Chairman Resigns
Ajay Kumar Dhadha stepped down as Chairman and Director, effective June 30, 2026. No disagreement was cited.
-
CFO and General Counsel Resigns
Effective July 16, 2026, Guy Ofir resigned from his roles as CFO, General Counsel, and Director. No disagreement was cited.
-
New CFO Appointed
Filling the vacancy left by Ofir, Uri Tadelis was appointed CFO effective July 16, 2026.
-
Leadership Void Amid Cash Crisis
The departures follow a May 2026 10-Q that revealed only $1,000 in cash and a going concern warning, heightening uncertainty about the company's ability to navigate its financial distress.
Analysis · RAPH · Life Sciences
Within weeks of each other, Chairman Ajay Kumar Dhadha and CFO/General Counsel Guy Ofir both resigned, stripping the company of its top financial and governance leaders. The departures hit as Raphael Pharmaceutical disclosed just $1,000 in cash and a going concern warning in May 2026. While the appointment of Uri Tadelis as CFO offers some continuity, the simultaneous loss of the chairman and CFO raises serious questions about stability at a critical juncture.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1498 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RAPH was trading at $1.40 on OTC in the Life Sciences sector, with a market capitalization of approximately $28.2M. The 52-week trading range was $0.04 to $2.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.